The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index; 1 of the 59 sources its claims cite were checked for support.
Preclinical Evidence of Alzheimer's Disease in Persons Homozygous for the ε4 Allele for Apolipoprotein E
Open accessAbstract
BACKGROUND: Variants of the apolipoprotein E allele appear to account for most cases of late-onset Alzheimer's disease, and persons with two copies of the epsilon 4 allele appear to have an especially high risk of dementia. Positron-emission tomography (PET) has identified specific regions of the brain in which the rate of glucose metabolism declines progressively in patients with probable Alzheimer's disease. We used PET to investigate whether these same regions of the brain are affected in subjects homozygous for the epsilon 4 allele before the onset of cognitive impairment. METHODS: Apolipoprotein E genotypes were established in 235 volunteers 50 to 65 years of age who reported a family history of probable Alzheimer's disease. Neurologic and psychiatric evaluations, a battery of neuropsychological tests, magnetic resonance imaging, and PET were performed in 11 epsilon 4 homozygotes and 22 controls without the epsilon 4 allele who were matched for sex, age, and level of education. An automated method was used to generate an aggregate surface-projection map that compared regional rates of glucose metabolism in the two groups. RESULTS: The epsilon 4 homozygotes were cognitively normal. They had significantly reduced rates of glucose metabolism in the same posterior cingulate, parietal, temporal, and prefrontal regions as in previously studied patients with probable Alzheimer's disease. They also had reduced rates of glucose metabolism in additional prefrontal regions, which may be preferentially affected during normal aging. CONCLUSIONS: In late middle age, cognitively normal subjects who are homozygous for the epsilon 4 allele for apolipoprotein E have reduced glucose metabolism in the same regions of the brain as in patients with probable Alzheimer's disease. These findings provide preclinical evidence that the presence of the epsilon 4 allele is a risk factor for Alzheimer's disease. PET may offer a relatively rapid way of testing future treatments to prevent Alzheimer's disease.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In cognitively normal late-middle-aged ε4 homozygotes with a family history of probable Alzheimer's disease, PET showed reduced glucose metabolism in the same posterior cingulate, parietal, temporal, and prefrontal regions as in probable Alzheimer's disease, plus additional prefrontal reductions. These findings provide preclinical evidence that the ε4 allele is a risk factor for Alzheimer's disease and suggest PET may help test prevention therapies.
Key findings
- Among 11 ε4 homozygotes and 22 non-ε4 controls matched for sex, age, and education, neuropsychological tests showed no significant differences in verbal memory, visual memory, naming, or visuospatial/constructional skills; MMSE scores were 29.4±0.8 vs. 29.8±0.6.
- PET showed no significant whole-brain glucose metabolism difference (5.1±1.0 vs. 5.2±0.8 mg/min/100 g, P=0.62) or pontine difference (5.0±1.0 vs. 5.0±0.7, P=0.90), but ε4 homozygotes had significant bilateral reductions in the same posterior cingulate, parietal, temporal, and prefrontal regions as probable Alzheimer's disease; the text reports a maximal posterior cingulate z score of 8.26 (P<0.001), while Table 4 lists z=6.58 for posterior cingulate.
- ε4 homozygotes also had significant reductions in additional prefrontal regions (maximal z=4.76, P<0.001 without correction for multiple comparisons), which the authors suggest may reflect accelerated aging.
- One ε4 homozygote had neuropsychological evidence of mild cognitive impairment and the greatest metabolic reductions; excluding his data only minimally affected group means, and reductions remained.
Methods
- Apolipoprotein E genotypes were established in 235 volunteers aged 50 to 65 who reported a family history of probable Alzheimer's disease in at least one first-degree relative; 12 ε4 homozygotes were identified, and 11 underwent imaging.
- For each ε4 homozygote, 2 controls without the ε4 allele (6 ε2/ε3 and 16 ε3/ε3) were matched for sex, age within 3 years, and education within 2 years; subjects had neurologic and psychiatric evaluations, a neuropsychological battery, MRI, and FDG PET.
- An automated three-dimensional stereotactic surface-projection algorithm compared regional glucose metabolism in ε4 homozygotes vs. controls and superimposed results on a prior probable-Alzheimer's disease map (37 patients vs. 22 normal controls); a critical z score of 4.32 identified voxels significant after correction for 278 resolution elements (P<0.05), with post hoc unpaired two-tailed t-tests.
Limitations
- The paper states the findings should be considered preliminary; no attempt was made to address the combined effect of atrophy and partial-volume averaging on whole-brain or regional measurements.
- The paper states that apolipoprotein E genotypes cannot predict whether or when Alzheimer's disease will develop, and that prospective longitudinal studies have not yet specified genotype-specific risks, onset ages, or attributable fractions; genotype-specific preventive therapies have not been identified.
- Evident from the text: the imaging sample was small (11 ε4 homozygotes vs. 22 controls), the design was cross-sectional without longitudinal follow-up, and one ε4 homozygote had mild cognitive impairment and was excluded in a sensitivity analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
28 Not checked yet · 16 Own result · 10 Own interpretation · 3 Own method · 1 Supported so far · 1 No basis given
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In comparison with the control group, the group with probable Alzheimer's disease had significantly reduced rates of glucose metabolism bilaterally in prefrontal (PF), parietal, temporal, and posterior cingulate (PC) regions.12,13”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > DISCUSSION
What the sources say
- Supportedcites [12] source
The paper compares FDG images from 37 patients with probable Alzheimer’s disease and 22 controls. Its figure caption reports statistically significant metabolic reduction on images of each hemisphere, identifying frontal, parietal, and temporal neocortex and posterior cingulate cortex. The paper calls the frontal region “frontal association cortex” rather than “prefrontal.” (LLM, conf=0.88)
- Not checked yetcites [13] Minoshima S, 1995, J Nucl Med
plaincorrelationaln = 37 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“They had significantly reduced rates of glucose metabolism in the same posterior cingulate, parietal, temporal, and prefrontal regions as in previously studied patients with probable Alzheimer's disease.”
- Also stated in: § PET · plain
“The group of e 4 homozygotes had significant bilateral reductions in glucose metabolism in the same posterior cingulate, parietal, temporal, and prefrontal regions as the group with probable Alzheimer's disease (Fig. 2 and Table 4)”
- Also stated in: § DISCUSSION · plain
“we found that the presymptomatic e4 homozygotes had significantly reduced rates of glucose metabolism in the same parietal, temporal, prefrontal, and posterior cingulate regions as patients with probable Alzheimer's disease.”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > Abstract
plaincorrelationaln = 22- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption: Cognitively normal e4 homozygotes in late middle age are in a presymptomatic stage of Alzheimer's disease.
- Also stated in: § PET · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“They also had reduced rates of glucose metabolism in additional prefrontal regions”
- Also stated in: § PET · plain
“The e4 homozygotes also had significant reductions in glucose metabolism in additional prefrontal regions (Fig. 2) (maximal z score, 4.76; PϽ0.001 without correction for multiple comparisons)”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § PET · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The e 4 homozygotes were cognitively normal.”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > Abstract
plainn = 22- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The exclusion of his data in a subsequent analysis only minimally affected the mean scores in the group of e 4 homozygotes.”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > Neuropsychological Tests
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the maximal reduction in glucose metabolism in the posterior cingulate cortex was significantly greater than those in the other regions (z score, 8.26; PϽ0.001).”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > PET
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no significant differences between the e 4 homozygotes and control subjects in the rates of wholebrain glucose metabolism (mean [ Ϯ SD], 5.1 Ϯ 1.0 vs. 5.2 Ϯ 0.8 mg per minute per 100 g; P ϭ 0.62 by twotailed, unpaired t-test)”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > PET
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The percentage of e 4 homozygotes in this sample was higher than that in the general population (5.1 percent vs. 2 to 3 percent), 8”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > R ESULTS
What the sources say
- Not checked yetcites [8] source
plaincorrelationaln = 235- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When his data were excluded in a subsequent analysis, glucose metabolism remained reduced”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > PET
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As compared with the control subjects, the e 4 homozygotes had slightly lower scores on the Mental Arithmetic test, Similarities test, and Freedom from Distractibility factor (measures of concentration and abstract reasoning)”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > Neuropsychological Tests
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 8
- Probably not a substantial claim. 15
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no significant differences between groups in verbal memory (as measured by the Auditory Verbal Learning Test), visual memory (as measured by the recall portion of the Complex Figure Test), naming (as assessed by the Boston Naming Test), or visuospatial and constructional skills (as assessed by the copy portion of the Complex Figure Test and the Block Design subtest of the Wechsler Adult”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > Neuropsychological Tests
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no significant differences in language skills or psychomotor speed (as measured by the Controlled Oral Word Association Test), estimates of premorbid intellectual function (as assessed by the Information subtest of the Wechsler Adult Intelligence Scale-Revised), or directed attention span (as assessed by the Digit Span subtest).”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > Neuropsychological Tests
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The metabolic reductions were greatest in an e4 homozygote with neuropsychological evidence of mild cognitive impairment, but were also apparent in the remaining, cognitively intact e4 homozygotes.”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“If, as case-control studies suggest, persons with two copies of the e 4 allele (the e 4/ e 4 genotype) have an especially high risk of Alzheimer's disease”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > V ARIANTS of the apolipoprotein E gene appear to
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“abnormally low prefrontal and whole-brain levels in more severely affected patients”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > V ARIANTS of the apolipoprotein E gene appear to
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“In contrast, the e 4 allele appears to be harmful, increasing the risk of Alzheimer's disease and hastening the onset of dementia.2,5”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > V ARIANTS of the apolipoprotein E gene appear to
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“When used to measure cerebral glucose metabolism, PET reveals characteristic abnormalities in patients with probable and definite Alzheimer's disease, including abnormally low parietal, temporal, and posterior cingulate levels”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > V ARIANTS of the apolipoprotein E gene appear to
What the sources say
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“and a progressive decline in these levels over time.”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > V ARIANTS of the apolipoprotein E gene appear to
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In a recent study, subjects with the apolipoprotein E e 3/ e 4 genotype, age-associated memory impairment, and a family history of Alzheimer's disease had abnormally low and asymmetric rates of glucose metabolism in a preselected parietal region before the onset of dementia.15”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > V ARIANTS of the apolipoprotein E gene appear to
What the sources say
- Not checked yetcites [15] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“which PET, [29][30][31]32 and neuropathological studies 33 suggest are preferentially affected during normal aging.”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > PET
What the sources say
- Not checked yetcites [29] source
- Not checked yetcites [30] Salmon E, 1991, Acta Neurol Belg
- Not checked yetcites [31] Loessner A, 1995, J Nucl Med
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Measurements in each voxel were normalized to that in the pons, which appears to be the region least affected in patients with Alzheimer's disease.27”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > Image Analysis
What the sources say
- Not checked yetcites [27] source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“which is affected in Alzheimer's disease, 34,35”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no significant differences in age, sex, handedness, years of education, age of the affected family member at the onset of dementia, scores on the Hamilton Depression Rating Scale, or scores on the Mini-Mental State Examination (range, 28 to 30 in both groups).”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > R ESULTS
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“A critical z score of 4.32 was used to identify voxels in which the homozygous group had significant reductions in glucose metabolism in the same regions as the patients with probable Alzheimer's disease (P Ͻ 0.05 after correction for the number of comparisons [i.e., the 278 resolution elements] in the searched volume 28 ) as well as in additional regions.”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > Image Analysis
What the sources say
- Not checked yetcites [28] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigators who were unaware of the subjects' apolipoprotein E genotypes obtained data from medical and family histories, a neurologic examination, a structured psychiatric interview, 20 the Folstein modified Mini-Mental State Examination (MMSE), 21 the Hamilton Depression Rating Scale, 22 a battery of neuropsychological tests, and brain-imaging studies.”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > Subjects
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Although the reductions in regional glucose metabolism could reflect decreased activity of terminal neuronal fields, 36 decreased density of terminal neuronal fields, atrophy, or some combination of these factors”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > DISCUSSION
What the sources say
- Not checked yetcites [36] source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For each of the 11 e 4 homozygotes who agreed to participate in the imaging studies, 2 control subjects without this allele (6 with the e 2/ e 3 genotype and 16 with the e 3/ e 3 genotype) were matched for sex, age (within three years), and level of education (within two years).”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > Subjects
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“PET may offer a relatively rapid way of testing future treatments to prevent Alzheimer's disease.”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > Abstract
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
In the paper
“an increased risk of coronary artery disease and fatal myocardial infarctions, [41][42][43]”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > DISCUSSION
What the sources say
- Not checked yetcites [41][42][43]
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“a decreased risk of coronary artery disease (unless it is associated with type III hyperlipoproteinemia), 42,43”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“the e2 allele has been associated with a decreased risk of Alzheimer's disease, 4”
§ PRECLINICAL EVIDENCE OF ALZHEIMER'S DISEASE IN PERSONS HOMOZYGOUS FOR THE e 4 ALLELE FOR APOLIPOPROTEIN E > DISCUSSION
What the sources say
- Not checked yetcites [4] source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
Cognitively normal e4 homozygotes in late middle age are in a presymptomatic stage of Alzheimer's disease.
“we found that the presymptomatic e4 homozygotes had significantly reduced rates of glucose metabolism in the same parietal, temporal, prefrontal, and posterior cingulate regions as patients with probable Alzheimer's disease.”
The paper relies on this without support.
Prospective, longitudinal studies of the general population have not yet specified the risk of Alzheimer's disease associated with each apolipoprotein E genotype, the mean age and variety of ages at the onset of dementia for each genotype, or the percentage of cases of Alzheimer's disease that are attributable to variants of the apolipoprotein E allele.
“Prospective, longitudinal studies of the general population have not yet specified the risk of Alzheimer's disease associated with each apolipoprotein E genotype, the mean age and variety of ages at the onset of dementia for each genotype, or the percentage of cases of Alzheimer's disease that are attributable to variants of the apolipoprotein E allele.”
The paper relies on this without support.
Genotype-specific preventive therapies have not yet been identified that might outweigh the psychological and social risks involved in making predictions about such a catastrophic illness.
“Genotype-specific preventive therapies have not yet been identified that might outweigh the psychological and social risks involved in making predictions about such a catastrophic illness.”
The paper relies on this without support.
The association between the e4 allele and Alzheimer's disease has been observed internationally in about 100 clinics.
“an association that has now been observed internationally in about 100 clinics.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our hypothesis, therefore, can accommodate a growing realization that for many subjects with suspected AD, or who have an increased risk of developing AD, what are currently considered downstream biomarker changes potentially precede upstream biomarker changes [206-213].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [209]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As shown in previous studies, the brains of APOE4 carriers display decreased glucose utilization in numerous AD-relevant brain regions, as observed by FDG-PET16–18.”
From APOE4 is Associated with Differential Regional Vulnerability to Bioenergetic Deficits in Aged APOE Mice (2020) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“early reports by Reiman and colleagues demonstrated that both young and old APOE4 carriers display decreased glucose utilization, as measured by fluorodeoxyglucose positron emission tomography (FDG-PET), in brain regions similar to those seen with AD patients16–18.”
From APOE4 is Associated with Differential Regional Vulnerability to Bioenergetic Deficits in Aged APOE Mice (2020) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Young, cognitively normal apoE4 carriers have glucose hypometabolism in brain regions affected by AD [29–31]”
From Neuronal Apolipoprotein E4 Expression Results in Proteome-Wide Alterations and Compromises Bioenergetic Capacity by Disrupting Mitochondrial Function (2019) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“[18F] fluorodeoxyglucose (FDG)-PET imaging showed hypometabolism in AD brains, mainly in the temporoparietal cortex including the precuneus and posterior cingulate cortex (Reiman et al., 1996; Foster et al., 2007).”
From APOE genotype-dependent differences in human astrocytic energy metabolism (2025) · cites this paper as Reiman et al., 1996
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As such, APOE4 is associated with increased Aβ deposition but accumulating evidence suggests that its influence on metabolic pathways may contribute to disease risk independently of Aβ [3][4][5][6][7] .”
From APOE4-drives brain bioenergetic shifts independent of Alzheimer’s disease pathology (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This suggests the possibility that an apoE-related decrease in brain metabolism may contribute to development of AD (Reiman et al., 1996; Reiman et al., 2004, 2005; Small et al., 2000).”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Reiman et al., 1996
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, studies looking at both young and old non-demented carriers of the apoE4 isoform observed a similar regional pattern of hypometabolism prior to the onset of disease that correlates with the changes seen in the AD brain.”
From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Reiman et al., 1996
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It has been suggested that this association may account for the earlier onset of symptoms in E4 carriers (21–23).”
From Prediction of cognitive decline in normal elderly subjects with 2-[ 18 F]fluoro-2-deoxy- d -glucose/positron-emission tomography (FDG/PET) (2001) · cites this paper as [22]
In the citing paper
“Moreover, both cross-sectional (21, 22) and longitudinal PET studies (23) show that nondemented E4 carriers have more hypometabolic regions than controls, but a relationship to longitudinally observed decline has not been reported.”
From Prediction of cognitive decline in normal elderly subjects with 2-[ 18 F]fluoro-2-deoxy- d -glucose/positron-emission tomography (FDG/PET) (2001) · cites this paper as [22]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Co-Planar Stereotaxic Atlas of the Human Brain
Talairach, J., & Tournoux, P. (1988) · Medical Entomology and Zoology · Cited by 11,798
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,565
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933
Research works printed but not linked: 11
- Roses AD, 1995, J NIH Res, 7, 51
- Mielke R, 1994, Dementia, 5, 36
- Minoshima S, 1995, J Nucl Med, 36, 1238
- Pietrini P, 1993, Dementia, 4, 94
- Spitzer RL, Williams JBW, Gibbon M, First MD. User's guide for the structured clinical interview for DSM-III-R (SCID). Washington, D.C.: American Psychiatric Press, 1990.
- Minoshima S, 1994, J Nucl Med, 35, 1528
- Salmon E, 1991, Acta Neurol Belg, 91, 288
- Loessner A, 1995, J Nucl Med, 36, 1141
- Davignon J, 1987, Trans Am Clin Climatol Assoc, 99, 100
- Wisniewski T, 1994, Am J Pathol, 145, 1030
- Kaplitt MG, 1995, Abstr Soc Neurosci, 21, 1008
Cited by
Sorted by citations
Items 301–400 of 1,002
Brain aging and Alzheimer's disease; use it or lose it
Swaab, D. F., Dubelaar, E. J. G., Hofman, M. A., Scherder, E., Someren, E. J. W. V., & Verwer, R. W. H. (2002) · Progress in brain research · doi:10.1016/s0079-6123(02)38086-5 · Cited by 119
Brain function and cognition in a community sample of elderly Latinos
Jagust, W. J., Eberling, J. L., Wu, C. C., Finkbeiner, A., Mungas, D., Valk, P. E., & Haan, M. N. (2002) · Neurology · doi:10.1212/wnl.59.3.378 · Cited by 118
Mild cognitive impairment and cognitive impairment, no dementia: Part A, concept and diagnosis
Chertkow, H. M., Nasreddine, Z. S., Joanette, Y., Drolet, V., Kirk, J., Massoud, F., Belleville, S., & Bergman, H. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.07.013 · Cited by 117
Lopez Lopez, C., Tariot, P. N., Caputo, A., Langbaum, J. B., Liu, F., Riviere, M., Langlois, C., Rouzade‐Dominguez, M., Zalesak, M., Hendrix, S., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.005 · Cited by 116
Self-citationCerebral glucose metabolism in patients with AD and different APOE genotypes
Drzezga, A., Riemenschneider, M., Strassner, B., Grimmer, T., Peller, M., Knoll, A., Wagenpfeil, S., Minoshima, S., Schwaiger, M., & Kurz, A. (2005) · Neurology · doi:10.1212/01.wnl.0000148478.39691.d3 · Cited by 116
Self-citationThe Neurodegenerative Mitochondriopathies
Swerdlow, R. H. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1095 · Cited by 115
Neuroimaging as a marker of the onset and progression of Alzheimer's disease
Masdeu, J. C., Zubieta, J. L., & Arbizu, J. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.05.001 · Cited by 114
Alzheimer's disease including focal presentations
Villain, N., & Dubois, B. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1681041 · Cited by 113
Johnson, S. C., La Rue, A., Hermann, B. P., Xu, G., Koscik, R. L., Jonaitis, E. M., Bendlin, B. B., Hogan, K. J., Roses, A. D., Saunders, A. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.11.012 · Cited by 112
Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer’s disease
Hattori, N., Abe, K., Sakoda, S., & Sawada, T. (2002) · Neuroreport · doi:10.1097/00001756-200201210-00041 · Cited by 112
Caselli, R. J., & Reiman, E. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129026 · Cited by 111
Self-citationLindstrom, H. A., Fritsch, T., Petot, G. J., Smyth, K. A., Chen, C. H., Debanne, S. M., Lerner, A. J., & Friedland, R. P. (2004) · Brain and Cognition · doi:10.1016/j.bandc.2004.09.020 · Cited by 111
Specificity of Brain Activation Patterns in People at Genetic Risk for Alzheimer Disease
Burggren, A. C., Small, G. W., Sabb, F. W., & Bookheimer, S. Y. (2002) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200201000-00006 · Cited by 111
Peng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
Positron emission tomography in clinical neurology
Herholz, K., & HEISS, W. (2004) · Molecular Imaging and Biology · doi:10.1016/j.mibio.2004.05.002 · Cited by 110
Normal Genetic Variation, Cognition, and Aging
Greenwood, P. M., & Parasuraman, R. (2003) · Behavioral and Cognitive Neuroscience Reviews · doi:10.1177/1534582303260641 · Cited by 110
Reconsider Alzheimer's disease by the ‘calpain–cathepsin hypothesis’—A perspective review
Yamashima, T. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.02.004 · Cited by 109
Pharmacogenomics in Alzheimer's Disease
Cacabelos, R. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-205-2_10 · Cited by 109
Roses, A. D., Saunders, A. M., Huang, Y., Strum, J. C., Weisgraber, K. H., & Mahley, R. W. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500397 · Cited by 109
Leoutsakos, J., Muthén, B., Breitner, J. C. S., & Lyketsos, C. G. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2723 · Cited by 109
Alzheimer’ s disease, oxidative stress and gammahydroxybutyrate
Mamelak, M. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.008 · Cited by 108
Kantarci, K., Smith, G. E., Ivnik, R. J., Petersen, R. C., Boeve, B. F., Knopman, D. S., Tangalos, E. G., & Jack, C. R. (2002) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617702870084 · Cited by 108
Functional activation imaging in aging and dementia
Prvulovic, D., van de Ven, V. G., Sack, A. T., Maurer, K., & Linden, D. E. J. (2005) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2005.06.006 · Cited by 108
The Cerebral Response during Subjective Choice with and without Self-reference
Johnson, S. C., Schmitz, T. W., Kawahara, T. N., Rowley, H. A., Alexander, A. L., Lee, J., & Davidson, R. J. (2005) · Journal of Cognitive Neuroscience · doi:10.1162/089892905775008607 · Cited by 108
APOE-4 Genotype and Neurophysiological Vulnerability to Alzheimer's and Cognitive Aging
Bookheimer, S. Y., & Burggren, A. C. (2009) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.032408.153625 · Cited by 108
Woodard, J. L., Grafton, S. T., Votaw, J. R., Green, R. C., Dobraski, M. E., & Hoffman, J. M. (1998) · Neuropsychology · doi:10.1037/0894-4105.12.4.491 · Cited by 108
Deeny, S. P., Poeppel, D., Zimmerman, J. B., Roth, S. M., Brandauer, J., Witkowski, S., Hearn, J. W., Ludlow, A. T., Contreras-Vidal, J. L., Brandt, J., et al. (2008) · Biological Psychology · doi:10.1016/j.biopsycho.2008.02.007 · Cited by 107
Nicholson, R. M., Kusne, Y., Nowak, L. A., LaFerla, F. M., Reiman, E. M., & Valla, J. (2010) · Brain Research · doi:10.1016/j.brainres.2010.05.084 · Cited by 107
Self-citationThe pyruvate dehydrogenase complex as a therapeutic target for age‐related diseases
Stacpoole, P. W. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2012.00805.x · Cited by 107
Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease
Honea, R. A., Swerdlow, R. H., Vidoni, E. D., Goodwin, J., & Burns, J. M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c918cb · Cited by 106
Biomarkers in Sporadic and Familial Alzheimer’s Disease
Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106
Tzimopoulou, S., Cunningham, V. J., Nichols, T. E., Searle, G. E., Bird, N., Mistry, P. C., Dixon, I. J., Hallett, W. A., Whitcher, B. J., Brown, A. P., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100939 · Cited by 106
Self-citationAerobic glycolysis in the primate brain: Reconsidering the implications for growth and maintenance
Bauernfeind, A. L., Barks, S. K., Duka, T., Grossman, L. I., Hof, P. R., & Sherwood, C. C. (2014) · Brain Structure and Function · doi:10.1007/s00429-013-0662-z · Cited by 105
Use of Functional Magnetic Resonance Imaging in the Early Identification of Alzheimer's Disease
Wierenga, C. E., & Bondi, M. W. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9025-y · Cited by 105
Vitali, P., Migliaccio, R., Agosta, F., Rosen, H., & Geschwind, M. D. (2008) · Seminars in Neurology · doi:10.1055/s-0028-1083695 · Cited by 105
Caselli, R. J., Chen, K., Lee, W., Alexander, G. E., & Reiman, E. M. (2008) · Archives of Neurology · doi:10.1001/archneurol.2008.1 · Cited by 105
Self-citationWomen at risk for AD show increased parietal activation during a fluency task
Smith, C. D., Andersen, A. H., Kryscio, R. J., Schmitt, F. A., Kindy, M. S., Blonder, L. X., & Avison, M. J. (2002) · Neurology · doi:10.1212/wnl.58.8.1197 · Cited by 105
Mitochondria in Alzheimer's disease and their potential role in Alzheimer's proteostasis
Weidling, I. W., & Swerdlow, R. H. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113321 · Cited by 104
Perfusion abnormalities in prodromal AD
Johnson, K. A., & Albert, M. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00137-8 · Cited by 104
Orr, A. L., Kim, C., Jimenez-Morales, D., Newton, B. W., Johnson, J. R., Krogan, N. J., Swaney, D. L., & Mahley, R. W. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-181184 · Cited by 103
Devous, M. D. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0967-2 · Cited by 103
Age-Related Regional Network of Magnetic Resonance Imaging Gray Matter in the Rhesus Macaque
Alexander, G. E., Chen, K., Aschenbrenner, M., Merkley, T. L., Santerre-Lemmon, L. E., Shamy, J. L., Skaggs, W. E., Buonocore, M. H., Rapp, P. R., & Barnes, C. A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1852-07.2008 · Cited by 103
Self-citationNutritional factors, cognitive decline, and dementia
Parigi, A. D., Panza, F., Capurso, C. A., & Solfrizzi, V. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.09.020 · Cited by 103
Altered deactivation in individuals with genetic risk for Alzheimer's disease
Persson, J., Lind, J., Larsson, A., Ingvar, M., Sleegers, K., Van Broeckhoven, C., Adolfsson, R., Nilsson, L.-G., & Nyberg, L. (2008) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2008.01.026 · Cited by 102
Pihlajamäki, M., & Sperling, R. A. (2009) · Behavioural Neurology · doi:10.1155/2009/276384 · Cited by 102
Preclinical Evidence of Alzheimer Changes
Petrie, E. C., Cross, D. J., Galasko, D. R., Schellenberg, G. D., Raskind, M. A., Peskind, E. R., & Minoshima, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.59 · Cited by 102
Self-citationThe scaling of spatial attention in visual search and its modification in healthy aging
Greenwood, P. M., & Parasuraman, R. (2004) · Perception & Psychophysics · doi:10.3758/bf03194857 · Cited by 102
Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions
Burns, C. M., Chen, K., Kaszniak, A. W., Lee, W., Alexander, G. E., Bandy, D. J., Fleisher, A., Caselli, R. J., & Reiman, E. M. (2013) · Neurology · doi:10.1212/wnl.0b013e31828f17de · Cited by 101
Self-citationUsing Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta
Cohen, A. D., Rabinovici, G. D., Mathis, C. A., Jagust, W. J., Klunk, W. E., & Ikonomović, M. D. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-394816-8.00002-7 · Cited by 103
EEG Alterations in Subjects at High Familial Risk for Alzheimer’s Disease
Пономарева, Н. В., Selesneva, N. D., & Jarikov, G. A. (2003) · Neuropsychobiology · doi:10.1159/000073633 · Cited by 101
PET-based molecular imaging in neuroscience
Jacobs, A. H., Li, H., Winkeler, A., Hilker, R., Knoess, C., R�ger, A., Galldiks, N., Schaller, B. J., Sobesky, J., Kracht, L. W., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1202-5 · Cited by 101
Genetic variation at a single locus and age of onset for Alzheimer's disease
Lutz, M. W., Crenshaw, D. G., Saunders, A. M., & Roses, A. D. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.01.011 · Cited by 101
Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies
Mistur, R. L., Mosconi, L., Santi, S. D., Guzman, M., Li, Y., Tsui, W., & de Leon, M. J. (2009) · Journal of Clinical Neurology · doi:10.3988/jcn.2009.5.4.153 · Cited by 101
Effects of Hormone Replacement Therapy on Cognitive and Brain Aging
Resnick, S. M., & Maki, P. M. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb04023.x · Cited by 101
Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence
Zandi, P. P. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00297-4 · Cited by 101
Langbaum, J. B. S., Chen, K., Caselli, R. J., Lee, W., Reschke, C., Bandy, D., Alexander, G. E., Burns, C. M., Kaszniak, A. W., Reeder, S. A., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.30 · Cited by 100
Self-citationCognitive reserve, presynaptic proteins, and dementia in the elderly
Honer, W. G., Barr, A. M., Sawada, K., Thornton, A. E., Morris, M. C., Leurgans, S. E., Schneider, J. A., & Bennett, D. A. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.38 · Cited by 100
The impact of hypertension on cerebral perfusion and cortical thickness in older adults
Alosco, M. L., Gunstad, J., Xu, X., Clark, U. S., Labbe, D. R., Riskin-Jones, H. H., Terrero, G., Schwarz, N. F., Walsh, E. G., Poppas, A., et al. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.04.002 · Cited by 99
Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer's brain
Mullins, R. J., Reiter, D. A., & Kapogiannis, D. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.530 · Cited by 98
Apolipoprotein E Genotype, Cortisol, and Cognitive Function in Community-Dwelling Older Adults
Lee, B. K., Glass, T. A., Wand, G. S., McAtee, M. J., Bandeen‐Roche, K., Bolla, K. I., & Schwartz, B. S. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07091532 · Cited by 98
The effect of APOE genotype on clinical phenotype in Alzheimer disease
van der Flier, W. M., Schoonenboom, S. N. M., Pijnenburg, Y. A. L., Fox, N. C., & Scheltens, P. (2006) · Neurology · doi:10.1212/01.wnl.0000228222.17111.2a · Cited by 98
Natural history of Alzheimer’s disease
Honig, L. S., & Mayeux, R. P. (2001) · Aging Clinical and Experimental Research · doi:10.1007/bf03351476 · Cited by 98
APOE related alterations in cerebral activation even at college age
Scarmeas, N. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.053645 · Cited by 97
Translational research in central nervous system drug discovery
Hurko, O., & Ryan, J. L. (2005) · NeuroRx · doi:10.1602/neurorx.2.4.671 · Cited by 96
Brain aerobic glycolysis functions and Alzheimer’s disease
Vlassenko, A. G., & Raichle, M. E. (2014) · Clinical and Translational Imaging · doi:10.1007/s40336-014-0094-7 · Cited by 96
Babiloni, C., Benussi, L., Binetti, G. G., Cassetta, E., Forno, G. D., Percio, C. D., Ferreri, F., Ferri, R., Frisoni, G. B., Ghidoni, R., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20724 · Cited by 96
Topology-Based Kernels With Application to Inference Problems in Alzheimer's Disease
Pachauri, D., Chris Hinrichs, A., Chung, M. K., Johnson, S. C., & Singh, V. (2011) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2011.2147327 · Cited by 96
Filippi, M., & Agosta, F. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101854 · Cited by 95
Axonal energy metabolism, and the effects in aging and neurodegenerative diseases
Yang, S., Park, J. H., & Lu, H.-C. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00634-3 · Cited by 94
Espeseth, T., Greenwood, P. M., Reinvang, I., Fjell, A. M., Walhovd, K. B., Westlye, L. T., Wehling, E. I., Lundervold, A. J., Rootwelt, H., & Parasuraman, R. (2006) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/cabn.6.1.31 · Cited by 94
Ding, F., Yao, J., Zhao, L., Mao, Z., Chen, S., & Brinton, R. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059825 · Cited by 94
Neural substrates participating in acquisition of facial familiarity: an fMRI study
Kosaka, H., Omori, M., Iidaka, T., Murata, T., Shimoyama, T., Okada, T., Sadato, N., Yonekura, Y., & Wada, Y. (2003) · NeuroImage · doi:10.1016/s1053-8119(03)00447-6 · Cited by 94
Ishii, K., Sasaki, M., Yamaji, S., Sakamoto, S., Kitagaki, H., & Mori, E. (1997) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/bf00841407 · Cited by 94
Brain Ageing in the New Millennium
Trollor, J. N., & Valenzuela, M. (2001) · Australian & New Zealand Journal of Psychiatry · doi:10.1046/j.1440-1614.2001.00969.x · Cited by 93
Neuroimaging and APOE Genotype: A Systematic Qualitative Review
Cherbuin, N., Leach, L., Christensen, H. M., & Anstey, K. J. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000109150 · Cited by 93
Huang, C. C., Wahlund, L., Almkvist, O., Elehu, D., Svensson, L. A., Jonsson, T., Winblad, B. G., & Julin, P. (2003) · NeuroImage · doi:10.1016/s1053-8119(03)00168-x · Cited by 93
Mild cognitive impairment: Conceptual issues and structural and functional brain correlates
Saykin, A. J., & Wishart, H. A. (2003) · Seminars in Clinical Neuropsychiatry · doi:10.1053/scnp.2003.50002 · Cited by 93
Shi, J., Thompson, P. M., Gutman, B. A., & Wang, Y. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.04.018 · Cited by 92
Głodzik-Sobańska, L., Pirraglia, E., Bryś, M., Santi, S. D., Mosconi, L., Rich, K. E., Switalski, R., Louis, L. S., Sadowski, M. J., Martiniuk, F. T., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.019 · Cited by 92
Precision Nutrition for Alzheimer’s Prevention in ApoE4 Carriers
Norwitz, N. G., Saif, N., Ariza, I. E., & Isaacson, R. (2021) · Nutrients · doi:10.3390/nu13041362 · Cited by 92
Head, E., Lott, I. T., Patterson, D. W., Doran, E. W., & Haier, R. J. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11110 · Cited by 91
García‐Bueno, B., Caso, J. R., Perez‐Nievas, B. G., Lorenzo, P. L., & Leza, J. C. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301252 · Cited by 91
Gray matter network associated with risk for Alzheimer's disease in young to middle-aged adults
Alexander, G. E., Bergfield, K. L., Chen, K., Reiman, E. M., Hanson, K. D., Lin, L., Bandy, D. J., Caselli, R. J., & Moeller, J. R. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.01.014 · Cited by 91
Self-citationSalmon, É., Collette, F., Degueldre, C., Lemaire, C. F., & Franck, G. (2000) · Human Brain Mapping · doi:10.1002/(sici)1097-0193(200005)10:1 · Cited by 91
Effect of statins on Alzheimer’s disease biomarkers in cerebrospinal fluid
Riekse, R. G., Li, G., Petrie, E. C., Leverenz, J. B., Vavrek, D., Vuletic, S., Albers, J. J., Montine, T. J., Lee, V. M.-Y., Lee, M., et al. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-10408 · Cited by 90
Alzheimer's Disease: Cerebrovascular Dysfunction, Oxidative stress, and Advanced Clinical Therapies
Marlatt, M. W., Lucassen, P. J., Perry, G. L., Smith, M. A., & Zhu, X. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15206 · Cited by 90
Albrecht, F., Ballarini, T., Neumann, J., & Schroeter, M. L. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.11.004 · Cited by 89
Chhimpa, N., Singh, N., Puri, N., & Kayath, H. P. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220514 · Cited by 89
Wierenga, C. E., Dev, S. I., Shin, D. D., Clark, L. R., Bangen, K. J., Jak, A. J., Rissman, R. A., Liu, T. T., Salmon, D. P., & Bondi, M. W. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.58 · Cited by 89
Imaging Brain Effects of APOE4 in Cognitively Normal Individuals Across the Lifespan
Fouquet, M., Besson, F. L., Gonneaud, J., Joie, R. L., & Chételat, G. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9263-8 · Cited by 89
Can the emerging field of immunometabolism provide insights into neuroinflammation?
Lynch, M. A. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101719 · Cited by 88
Xu, G., McLaren, D. G., Ries, M. L., Fitzgerald, M. E., Bendlin, B. B., Rowley, H. A., Sager, M. A., Atwood, C., Asthana, S., & Johnson, S. C. (2008) · Brain · doi:10.1093/brain/awn254 · Cited by 88
Episodic memory in Alzheimer's disease: Separating response bias from discrimination
Budson, A. E., Wolk, D. A., Chong, H., & Waring, J. D. (2006) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2006.05.024 · Cited by 88
Molecular imaging in dementia: Past, present, and future
Laforce, R. J., Soucy, J., Sellami, L., Dallaire‐Théroux, C., Brunet, F., Bergeron, D., Miller, B. L., & Ossenkoppele, R. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.06.2855 · Cited by 88
The Alzheimer’s Disease Mitochondrial Cascade Hypothesis: A Current Overview
Swerdlow, R. H. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221286 · Cited by 88
Role of GSK‐3β in Alzheimer's disease pathology
Planel, E., Sun, X., & Takashima, A. (2002) · Drug Development Research · doi:10.1002/ddr.10100 · Cited by 87
Prognostic Value of Posteromedial Cortex Deactivation in Mild Cognitive Impairment
Petrella, J. R., Prince, S. E., Wang, L., Hellegers, C., & Doraiswamy, P. M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001104 · Cited by 87
Fan, J., Tao, W., Li, X., Li, H., Zhang, J., Wei, D., Chen, Y., & Zhang, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051177 · Cited by 87
Roses, A. D. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s340 · Cited by 86
Cognitive and neural signatures of the APOE E4 allele in mid-aged adults
Evans, S., Dowell, N. G., Tabet, N., Tofts, P. S., King, S. L., & Rusted, J. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.145 · Cited by 86
Metadata
- Authors
- Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D.
- Affiliations
- University of Arizona (US)
- Mayo Clinic in Arizona (US)
- University of Michigan (US)
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1996-03-21
- Volume
- 334
- Issue
- 12
- Pages
- 752-758
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2023121717
- Semantic Scholar
- a04d6dd3638573927f661225155d8ef1ee0fff4d
- Cited by
- 1,366
- References
- 44
- Citations by year
- 2026: 15 · 2025: 10 · 2024: 20 · 2023: 28 · 2022: 28 · 2021: 27 · 2020: 30 · 2019: 30 · 2018: 40 · 2017: 41 · 2016: 42 · 2015: 37 · 2014: 53 · 2013: 56 · 2012: 64
- FWCI
- 42.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Academy of Neurology
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, apolipoprotein E, ε4 allele, homozygosity, preclinical Alzheimer's disease, glucose metabolism, positron emission tomography, brain glucose hypometabolism, family history of Alzheimer's disease, prefrontal cortex, posterior cingulate cortex, parietal cortex, temporal cortex, normal aging, genetic risk factors
- MeSH terms
- Aged, Alleles, Alzheimer Disease, Apolipoproteins E, Brain, Female, Genotype, Glucose, Homozygote, Humans, Image Processing, Computer-Assisted, Male, Middle Aged, Neuropsychological Tests, Tomography, Emission-Computed, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
